(firstQuint)Phase 1 Study of CM082 in Patients With Wet-AMD.

 This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With wet-AMD.

 Patients will receive one of four doses for up to four weeks.

 Single/multiple dose pharmacokinetics in these patients will be studied.

 At the end of four weeks, investigator will evaluate safety and tolerability and decide whether to continue treatment for a total of six months to further evaluate safety and preliminary efficacy.

.

 Phase 1 Study of CM082 in Patients With Wet-AMD@highlight

This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With wet-AMD.

